US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% TSLA $370.59 ▲+0.00% SDEV $7.48 ▲+0.00% AMD $633.91 ▲+0.00%
FinancialContent

Articles published by Structure Therapeutics Inc.

News headline image
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR
News headline image
Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer
From Structure Therapeutics Inc.
Via GlobeNewswire
Tickers GPCR